Patents Examined by Esther M. Kepplinger
  • Patent number: 5372931
    Abstract: Aqueous compositions, test kits, test devices and methods can be used to detect hydrogen peroxide or peroxidase by generating a colorimetric or chemiluminescent signal in the presence of the analyte. Signal generation is enhanced by the presence of certain substituted 4-hydroxy- or 4-alkoxy-substituted phenyl or naphthyl electron transfer agents.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 13, 1994
    Assignee: Eastman Kodak Company
    Inventors: Alan E. Friedman, Thomas R. Kissel
  • Patent number: 5372948
    Abstract: Disclosed are a method and device for performing sequential analytical reactions involving a first dry reagent and a second dry reagent comprised of two or more components having different rates of solubilization. The invention enables one to fully solubilize the components of the second reagent before they are brought into contact with each other to thereby avoid interference with the reaction kinetics which result when one or both of the components are not fully dissolved prior to their being brought into contact. The invention is especially useful in conjunction with immunoassay formats involving latex bound antibodies and polymeric agglutinators.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: December 13, 1994
    Assignee: Miles Inc.
    Inventor: Kin F. Yip
  • Patent number: 5372932
    Abstract: A dry analytical element can be used to sensitively and rapidly detect a wide variety of specific binding ligands in either a competitive binding or sandwich assay format. The assays are carried out using a peroxidase-labeled immunoreactant. The peroxidase label is stabilized with a 4-hydroxy or 4-alkoxyarylacetamide which is located in one or more zones of the element. Not only is the label stabilized with the stabilizer, but the assay is more sensitive.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 13, 1994
    Assignee: Eastman Kodak Company
    Inventors: Alan E. Friedman, Linda A. Mauck, Thomas R. Kissel
  • Patent number: 5370993
    Abstract: Compounds and methods are disclosed for reversibly aggregating particles suspended in a liquid medium. The method comprises combining the liquid medium containing the particles with a polyionic polymer capable of aggregating the particles under conditions suitable for such aggregation. Thereafter, the particles are contacted with a chemical reagent capable of cleaving the polyionic polymer under conditions sufficient to reverse the aggregation. Optionally, magnetic particles are added to the liquid medium in the present method under conditions for non-specific binding and the medium including the aggregates is subjected to a magnetic field gradient to separate the aggregates from the medium. The compounds of the present invention are polyions. The aggregation of the particles is reversible upon contact with chemical agents which cleave at least some of the bonds within the polyionic polymer.
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: December 6, 1994
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Thomas L. Tarnowski, Cheng-I Lin, Edwin F. Ullman
  • Patent number: 5369002
    Abstract: An easy method for detecting injured cell nuclear DNA is provided which does not suffer from "pseudo-positive" staining. The method comprises the steps of subjecting a pathological tissue specimen to acid-hydrolysis to selectively hydrolyze any injured DNA thereby to form single-stranded DNA, then treating the specimen with an anti-single-stranded DNA antibody, and subjecting the specimen to morphological inspection to find the presence of the binding of the antibody to the single-stranded DNA. The binding may be discriminated by a labelling marker on the antibody. Alternatively, a labelled secondary antibody which binds to the anti-ssDNA antibody may be used.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: November 29, 1994
    Assignee: Maruzen Petrochemical Co., Ltd.
    Inventor: Masaru Fukuda
  • Patent number: 5369011
    Abstract: This invention relates to a method for collecting, concentrating and detecting microorganisms from difficult-to-separate environmental samples e.g. oil well samples and the like, for the purpose of their analysis or identification; and apparatus for performing the method.
    Type: Grant
    Filed: June 16, 1992
    Date of Patent: November 29, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Richard C. Ebersole, Frank T. Gelormini
  • Patent number: 5369036
    Abstract: A process for assaying at least one analyte uses a tracer which includes multiple detectable substances. A tracer composition includes at least one ligand labeled with a particulate label, the particulate label containing at least one detectable substance. Two or more detectable substances in the assay may be in the same particulate label or in different particulate labels conjugated to different ligands.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: November 29, 1994
    Assignee: Becton, Dickinson and Company
    Inventors: Thomas J. Mercolino, Joanne H. Hasskamp, Edward C. McFarland
  • Patent number: 5366862
    Abstract: The invention allows the generation and screening of a large population of peptides for the presence of peptides which bind a particular macromolecule or macromolecular complex with high affinity, and further allows the favored net synthesis of analyzable quantities of such peptides, by using as the "trap" a macromolecule or macromolecular complex for which binding of the peptide is desired. The starting mixture is preferably spiked with a peptide having some affinity for the target macromolecule so that mutation of the spike or "lead" peptide is favored. The development of improved binding peptides through scrambling may be dynamically monitored by initially binding the target with an insolubilized ligand, and then looking for an increase in the concentration of the target in the soluble phase as a result of the displacement of the reference ligand by scrambled peptides.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: November 22, 1994
    Assignee: Receptor Laboratories, Inc.
    Inventors: Duane L. Venton, Anton J. Hopfinger, Guy Le Breton
  • Patent number: 5358849
    Abstract: The present invention first provides monoclonal antibodies recognizing membrane phospholipase A.sub.2, namely, monoclonal antibodies PL-49, PL-71, PL-76, and PL-78, hybridomas producing them, methods for producing them, and immunoassays of membrane phospholipase A.sub.2 using them.The immunoassay of PLA.sub.2 M is useful for the diagnosis of articular rheumatism, cancers, and a wide variety of inflammatory states.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: October 25, 1994
    Assignee: Shionogi & Co., Ltd.
    Inventors: Nobuo Yoshida, Misao Ide, Masao Kono, Akiko Kanda
  • Patent number: 5358850
    Abstract: The present invention relates to a process of preparing a sandwich immunoassay of NAG, which comprises (1) reacting NAG with an immobilized anti-NAG monoclonal antibody and a labeled anti-NAG monoclonal antibody to form a complex of immobilized antibody-NAG-labeled antibody and (2) detecting the activity of said reacted and unreacted labeled anti-NAG antibody.This sandwich immunoassay is useful for diagnosis of renal disease, hepatitis, leukemia, and other such diseases. It also allows the direct and specific detection of NAG isozymes B and I in urine and blood.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: October 25, 1994
    Assignee: Shionogi Seiyaku Kabushiki Kaisha
    Inventors: Yoshito Numata, Yoko Kosugi, Kazunori Shibata
  • Patent number: 5356781
    Abstract: Pancreatic disease can be diagnosed by assaying a patient's body fluid such as serum or urine, for pancreatic activation peptides (PAP) released from zymogens by proteolytic activation. Particularly useful are peptides having C-terminal D.sub.4 K sequences. The method uses polyclonal or monoclonal antibodies generated and selected for C-terminal specificity on PAP so that the tests only report free PAP not parent zymogen. Also described are peptides and antibodies labelled with revealing agents and/or immobilised on solid supports and their use in diagnostic assays and kits. In pancreatic disease the tests distinguish necrotising from oedematous acute pancreatitis and permit severity prediction and monitoring as well as diagnosing chronic pancreatitis in exacerbation.
    Type: Grant
    Filed: June 26, 1991
    Date of Patent: October 18, 1994
    Assignee: Bioscience International, Inc.
    Inventors: John Hermon-Taylor, Brian M. Austen
  • Patent number: 5356783
    Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: October 18, 1994
    Assignee: W. Alton Jones Cell Science Center, Inc.
    Inventors: Vincenzo Buonassisi, Patricia C. Colburn
  • Patent number: 5352575
    Abstract: The present invention provides recombinant DNA molecules comprising a sequence encoding a pseudorabies virus (PRV) glycoprotein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gI, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRV, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: October 4, 1994
    Assignee: The Upjohn Company
    Inventors: Erik A. Petrovskis, Leonard E. Post, James G. Timmins
  • Patent number: 5350697
    Abstract: An apparatus in which scattered light is measured, said apparatus having a light source aligned to direct illumination toward an interface between a sample container and an aqueous solution at an angle less than the critical angle. A detector to measure the scattered light is located at a place outside the envelope of the critical angle.
    Type: Grant
    Filed: August 28, 1990
    Date of Patent: September 27, 1994
    Assignee: Akzo N.V.
    Inventors: C. Hermas Swope, John G. Link, Jones M. Hyman
  • Patent number: 5342756
    Abstract: The degradation of type III collagen in the body is quantitatively determined by measuring the concentration of the liberated aminoterminal telopeptide region of the type III collagen molecule in the body fluid by a specific immunological method. This degredation product is resistant to further degradation and can thus be found in body fluids e.g. in serum or urine. For the determination the telopeptide region must be isolated from a human source e.g. from uterine leiomyoma.
    Type: Grant
    Filed: December 5, 1989
    Date of Patent: August 30, 1994
    Assignee: Orion-Yhtyma Oy
    Inventors: Juha Risteli, Leila Risteli
  • Patent number: 5320941
    Abstract: This invention provides a DNA sequence comprising an activated oncogene, said oncogene encoding a polypeptide capable of transforming NIH3T3 cells and of inducing a tumor when injected into nude mice, said DNA sequence having a nucleotide sequence substantially as shown in FIGS. 3A and 3B.The invention also concerns a polypeptide molecule encoded by an activated oncogene, said molecule having the properties of transforming NIH3T3 cells and of inducing a tumor when injected into nude mice and further said polypeptide having an amino acid sequence substantially as shown in FIGS. 3A and 3B.Finally, this invention provides a method for treating a tumor induced by an activated mas oncogene.
    Type: Grant
    Filed: June 6, 1986
    Date of Patent: June 14, 1994
    Inventors: Dallan Young, Michael H. Wigler, Ottavio Fasano
  • Patent number: 5240844
    Abstract: A test card incorporates a colorimetric indicator test to determine the presence of a minute amount of a specific substance in a liquid medium. The test card includes top and bottom sheets adhesively secured to an intermediate frame member which, together with the top and bottom sheets, defines a filter chamber having a flat filter therein which incorporates a test portion. The test portion of the filter has a binding substrate to which antibodies of the specific substance have been bound. This binding substrate is in communication with a test port. In the method of the invention a substance to be tested is administered through the test port and contains an unknown amount of antigen. After the sample is administered an aqueous solution of enzyme labelled antigen is administered and, subsequently, a liquid substrate is added to cause a color change in the filter below the test port inversely proportional to the amount of antigen contained in the sample administered at the test port.
    Type: Grant
    Filed: March 14, 1988
    Date of Patent: August 31, 1993
    Inventors: Siong I. Wie, Arden A. Kelton
  • Patent number: 5110738
    Abstract: The present invention is concerned with a monoclonal antibody capable of preferentially recognizing arteriosclerotic lesions and prepared from a hybridoma obtained by fusing myeloma cells and cells capable of producing antibodies against arteriosclerotic lesions, such as spleen cells, peripheral lymphocyte of thymus and peripheral vascular cells, the antibody can be to use as an agent for detecting the presence of arteriosclerotic lesions and for treating arteriosclerosis.
    Type: Grant
    Filed: December 14, 1987
    Date of Patent: May 5, 1992
    Assignee: Research Development Corporation of Japan
    Inventors: Tatsuya Takano, Ryoichi Hashida, Keiji Nakagami, Junji Kimura
  • Patent number: 5108896
    Abstract: The present invention relates to dual analyte enzyme immunoassays for assaying two antigens in a single liquid sample wherein the two immunoreactions are carried out simultaneously and wherein subsequently the two enzyme reactions occur simultaneously. Suitable enzyme/substrate pairs are beta-galactosidase/nitrophenyl-beta-D-galactoside (p- an/or o-) and alkaline phosphatase/phenolphthalein monophosphate.
    Type: Grant
    Filed: March 2, 1987
    Date of Patent: April 28, 1992
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Roger D. Philo, Gerald J. Allen
  • Patent number: 5102786
    Abstract: There is provided a biological diagnostic assay system wherein a phenoxy-substituted naphthalene compound, such as phenoxynaphthalene sulfonate, or a salt thereof, is utilized to prevent plasma proteins such as serum albumin from binding to other components of the assay and/or to displace plasma proteins which have become bound to other components of the assay.
    Type: Grant
    Filed: May 21, 1987
    Date of Patent: April 7, 1992
    Assignee: PB Diagnostic Systems, Inc.
    Inventors: Saul G. Cohen, Shai Inbar